Ultrasound-guided synovial biopsy: a safe, well-tolerated and reliable technique for obtaining high-quality synovial tissue from both large and small joints in early arthritis patients

2013/12/14 by S Kelly, S. Kelly, Frances Humby +23 · 28 citations
Medicine · #Rheumatoid Arthritis Research and Therapies #Musculoskeletal synovial abnormalities and treatments #Autoimmune and Inflammatory Disorders Research

paper · doi:10.1136/annrheumdis-2013-204603

Cited by

• Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients
• IL-23 skin and joint profiling in psoriatic arthritis: novel perspectives in understanding clinical responses to IL-23 inhibitors
• Rheumatoid arthritis susceptibility genes show pathotype-specific expression in synovial tissue of patients with early treatment-naïve RA
• Expression of chemokines CXCL4 and CXCL7 by synovial macrophages defines an early stage of rheumatoid arthritis. [europepmc]
• Immune cell profiling to guide therapeutic decisions in rheumatic diseases. [europepmc]
• Single cell cloning and recombinant monoclonal antibodies generation from RA synovial B cells reveal frequent targeting of citrullinated histones of NETs. [europepmc]
• Integrative genomic deconvolution of rheumatoid arthritis GWAS loci into gene and cell type associations. [europepmc]
• Immunopathogenesis of Rheumatoid Arthritis. [europepmc]
• Identification of a transitional fibroblast function in very early rheumatoid arthritis. [europepmc]
• Triple DMARD treatment in early rheumatoid arthritis modulates synovial T cell activation and plasmablast/plasma cell differentiation pathways. [europepmc]
• Transcriptional Profiling of Synovial Macrophages Using Minimally Invasive Ultrasound-Guided Synovial Biopsies in Rheumatoid Arthritis. [europepmc]
• Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients. [europepmc]
• Activation of naïve CD4 + T cells re-tunes STAT1 signaling to deliver unique cytokine responses in memory CD4 + T cells. [europepmc]
• Synovial Tissue Heterogeneity in Rheumatoid Arthritis and Changes With Biologic and Targeted Synthetic Therapies to Inform Stratified Therapy. [europepmc]
• HBEGF + macrophages in rheumatoid arthritis induce fibroblast invasiveness. [europepmc]
• Can Metabolic Pathways Be Therapeutic Targets in Rheumatoid Arthritis? [europepmc]
• The macrophage tetraspan MS4A4A enhances dectin-1-dependent NK cell-mediated resistance to metastasis. [europepmc]
• Molecular Portraits of Early Rheumatoid Arthritis Identify Clinical and Treatment Response Phenotypes. [europepmc]
• Interleukin-36 family dysregulation drives joint inflammation and therapy response in psoriatic arthritis. [europepmc]
• Synovial tissue signatures enhance clinical classification and prognostic/treatment response algorithms in early inflammatory arthritis and predict requirement for subsequent biological therapy: results from the pathobiology of early arthritis cohort (PEAC). [europepmc]
• Lactate Buildup at the Site of Chronic Inflammation Promotes Disease by Inducing CD4 + T Cell Metabolic Rewiring. [europepmc]
• B Cell Synovitis and Clinical Phenotypes in Rheumatoid Arthritis: Relationship to Disease Stages and Drug Exposure. [europepmc]
• A Pauci-Immune Synovial Pathotype Predicts Inadequate Response to TNFα-Blockade in Rheumatoid Arthritis Patients. [europepmc]
• IL-23 skin and joint profiling in psoriatic arthritis: novel perspectives in understanding clinical responses to IL-23 inhibitors. [europepmc]
• Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. [europepmc]
• Differential expression and regulation of MS4A family members in myeloid cells in physiological and pathological conditions. [europepmc]
• Macrophages: The Good, the Bad, and the Gluttony. [europepmc]
• Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial. [europepmc]